Risk of Estrogen Receptor–Positive and –Negative Breast Cancer and Single–Nucleotide Polymorphism 2q35-rs13387042Roger L. Milne, Hiltrud Brauch, Alfons Meindl et al.|JNCI Journal of the National Cancer Institute|2009Cited by 107
Association Between a Germline OCA2 Polymorphism at Chromosome 15q13.1 and Estrogen Receptor–Negative Breast Cancer SurvivalElizabeth M. Azzato, Hoda Anton‐Culver, Jonathan P. Tyrer et al.|JNCI Journal of the National Cancer Institute|2010Cited by 50
Missense Variants in <i>ATM</i> in 26,101 Breast Cancer Cases and 29,842 ControlsOlivia Fletcher, Yon‐Dschun Ko, Nichola Johnson et al.|Cancer Epidemiology Biomarkers & Prevention|2010Cited by 40
Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2Tomas Kirchhoff, Fleur Hammet, Mia M. Gaudet et al.|PLoS ONE|2012Cited by 13
SNP rs2180341 per-allele hazard ratios (HRs) and 95% confidence intervals (CIs) among Consortium of Investigators of Modifiers of <i>BRCA1/2</i> (CIMBA) in A. <i>BRCA1</i> mutation carriers B. <i>BRCA2</i> mutation carriers.Tomas Kirchhoff, Thijs Van Dorpe, Mia M. Gaudet et al.|Figshare|2015Cited by 0